US2007066538A1PendingUtilityA1
Treatment of wounds
Est. expiryOct 22, 2019(expired)· nominal 20-yr term from priority
Inventors:David Pritchard
A61K 38/00A61L 15/32C07K 14/43577
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
An isolated protein, for use in treatment of wounds, is characterized in that it is secreted by the organism Lucilia sericata and it exhibits proteolytic activity against FITC-casein at a pH of 8.0 to 8.5. The protein exhibits proteolytic activity against Tosyl-Gly-Pro-Arg-AMC but not against Suc-Ala-Ala-Phe-AMC, and its proteolytic activity against FITC-casein and Tosyl-Gly-Pro-Arg-AMC is inhibited by the serine proteinase inhibitors PMSF and AMPSF. The protein is also bound by immobilized aminobenzamidine.
Claims
exact text as granted — not AI-modified1 . (canceled)
2 . The method of claim 6 , wherein the isolated protein has a molecular weight of approximately 25 kDa.
3 . (canceled)
4 . The method of claim 6 , wherein the isolated protein is secreted by an insect in its larval stage.
5 . (canceled)
6 . A method for treating a wound to promote healing thereof in a human or non-human mammal, which comprises applying to the wound a therapeutically effective amount of:
(a) an isolated protein characterized in that:
i) it is secreted by the organism Lucilia sericata;
ii) it exhibits optimum proteolytic activity against FITC-casein at a pH of 8.0 to 8.5;
iii) it exhibits proteolytic activity against Tosyl-Gly-Pro-Arg-AMC but not against Suc-Ala-Ala-Phe-AMC;
iv) its proteolytic activity against FITC-casein and Tosyl-Gly-Pro-Arg-AMC is inhibited by the serine proteinase inhibitors PMSF and APMSF; and
v) it is bound by immobilized aminobenzamidine; or
(b) one or more peptides selected from the group consisting of Ser-Phe-Leu-Leu-Arg-Asn (SEQ ID NO: 1); Ser-Leu-Ile-Gly-Lys-Val (SEQ ID NO: 2); Thr-Phe-Arg-Gly-Ala-Pro (SEQ ID NO: 3); Gly-Tyr-Pro-Gly-Gln-Val ((SEQ ID NO: 4); a peptide having as an N-terminal sequence Ser-Phe-Leu-Leu-Arg-Asn (SEQ ID NO: 1), Ser-Leu-Ile-Gly-Lys-Val (SEQ ID NO: 2), Thr-Phe-Arg-Gly-Ala-Pro (SEQ ID NO: 3), or Gly-Tyr-Pro-Gly-Gln-Val (SEQ ID NO: 4); and analogues thereof which are protected against aminopeptidase activity.
7 . The method of claim 6 wherein the isolated protein or peptide is applied as a sterile composition comprising a therapeutically effective amount of the isolated protein or peptide and a sterile carrier therefore.
8 . (canceled)
9 . (canceled)
10 . An isolated peptide selected from the group consisting of
Ser-Phe-Leu-Leu-Arg-Asn (SEQ ID NO: 1); Ser-Leu-Ile-Gly-Lys-Val (SEQ ID NO: 2); Thr-Phe-Arg-Gly-Ala-Pro (SEQ ID NO: 3); Gly-Tyr-Pro-Gly-Gln-Val (SEQ ID NO: 4); a peptide having as an N-terminal sequence Ser-Phe-Leu-Leu-Arg-Asn (SEQ ID NO: 2), Ser-Leu-Ile-Gly-Lys-Val (SEQ ID NO: 2), Thr-Phe-Arg-Gly-Ala-Pro (SEQ ID NO:3), or Gly-Tyr-Pro-Gly-Gln-Val (SEQ ID NO: 4); and analogues thereof which are protected against aminopeptidase activity
11 . (canceled)
12 . (canceled)
13 . A dressing for a wound, which comprises a sterile support and isolated protein characterised in that:
i) it is secreted by the organism Lucilia sericata; ii) it exhibits optimum proteolytic activity against FITC-casein at a pH of 8.0 to 8.5; iii) it exhibits proteolytic activity against Tosyl-Gly-Pro-Arg-AMC but not against Suc-Ala-Ala-Phe-AMC; iv) its proteolytic activity against FITC-casein and Tosyl-Gly-Pro-Arg-AMC is inhibited by the serine proteinase inhibitors PMSF and APMSF; and v) it is bound by immobilised aminobenzamidine.
14 . A dressing for a wound, which comprises a sterile support and at least one peptide according to claim 10 .
15 . A protein which is protected against aminopeptidase activity, wherein the protein is characterized in that:
i) it is secreted by the organism Lucilia sericata; ii) it exhibits optimum proteolytic activity against FITC-casein at a pH of 8.0 to 8.5; iii) it exhibits proteolytic activity against Tosyl-Gly-Pro-Arg-AMC but not against Suc-Ala-Ala-Phe-AMC; iv) its proteolytic activity against FITC-casein and Tosyl-Gly-Pro-Arg-AMC is inhibited by the serine proteinase inhibitors PMSF and APMSF; and v) it is bound by immobilized aminobenzamidine.
16 . A protein which is protected against aminopeptidase activity, wherein the protein comprises at least one peptide according to claim 10 .
17 . The protein of claim 15 wherein protection against aminopeptidase activity is achieved by amidation at the COOH substitution in the protein using a non-coded anomalous amino acid.
18 . The protein of claim 15 wherein protection against aminopeptidase activity is achieved by replacing a CO—NH bond by an isostere.
19 . The protein of claim 15 wherein protection against aminopeptidase activity is achieved by amidation at the COOH substitution in the protein using a non-coded anomalous amino acid and by replacing a CO—NH bond by an isostere.
20 . A composition for the treatment of wounds comprising a therapeutically effective amount of a protein according to claim 6 and a sterile carrier therefore.
21 . The composition of claim 20 further comprising a material capable of delivering the protein to a wound in a slow release or controlled release manner.
22 . The composition of claim 21 wherein the material is poly(lactide-co-glycolide) or particles of PLGA.
23 . The composition of claim 20 wherein the protein is protected against aminopeptidase activity.
24 . The dressing of claim 13 wherein the protein is protected against aminopeptidase activity.
25 . The dressing of claim 13 further comprising slow-release colloidal particles.
26 . The dressing of claim 13 further comprising sponges.
27 . The dressing of claim 13 which is over layered by a conventional dressing.Join the waitlist — get patent alerts
Track US2007066538A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.